Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Controlled Trial to Compare Oxaliplatin Combined With S-1 (SOX) Versus Oxaliplatin With Capecitabine (XELOX) as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients

NCT03448549 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT03448549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03448549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Controlled Trial to Compare Oxaliplatin Combined With S-1 (SOX) Versus Oxaliplatin With Capecitabine (XELOX) as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 3
Overall status
Unknown status
Start date
January 1, 2018
Completion date
January 1, 2024
Enrollment
1,191 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant chemotherapy, colorectal cancer stage iii